ibx glp-1 coverage Medicaid of and Spending on GLP-1s Obesity Meds Advance, Insurance Retreats:

The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus

Lipid-lowering actions of sitagliptin are attenuated in HFD-fed Dpp4 EC/ , Dpp4 EC+/+ (BMT), and Dpp4 EC/ (BMT) mice

To assess whether the findings could be explained by GLP-1 RA-related weight loss, we conducted a counterfactual analysis in which we set pre-pregnancy BMI to values consistent with a scenario without treatment-related weight reduction and repeated the analyses

Coverage for weight loss specifically is still far from universal

Conclusion: Semaglutide represents a significant advancement in the treatment of type 2 diabetes and obesity

Liang, Y